Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Beelen

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|October 1, 1993
Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation studyD W Beelen, H G Sayer, M Franke, et al.
Bone Marrow Transplantation|August 1, 1996
Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantationA H Elmaagacli, D W Beelen, H W Becks, et al.
Bone Marrow Transplantation|September 1, 2000
Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia--a single center experience on 160 patientsJ Thiele, H M Kvasnicka, D W Beelen, et al.
Annals of Hematology|December 17, 2002
Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter studyD W Beelen, H Ottinger, K Kolbe, et al.
Onkologie|February 1, 1988
Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trialD W Beelen, U Graeven, G Schulz, et al.
Bone Marrow Transplantation|June 29, 2010
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndromeI Hilgendorf, D Wolff, T Gromke, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology studyD W Beelen, R B Schilcher, R Ehrlich, et al.
European Journal of Haematology|August 1, 1988
Bone marrow transplantation for myeloblastomaK Quabeck, D W Beelen, H K Mahmoud, et al.
Blood|January 7, 1998
Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerismD W Beelen, H D Ottinger, A Elmaagacli, et al.
Antimicrobial Resistance and Infection Control|October 1, 2016
Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantationM Krull, I Klare, B Ross, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|October 1, 1993
Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation studyD W Beelen, H G Sayer, M Franke, et al.
Bone Marrow Transplantation|August 1, 1996
Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantationA H Elmaagacli, D W Beelen, H W Becks, et al.
Bone Marrow Transplantation|September 1, 2000
Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia--a single center experience on 160 patientsJ Thiele, H M Kvasnicka, D W Beelen, et al.
Annals of Hematology|December 17, 2002
Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter studyD W Beelen, H Ottinger, K Kolbe, et al.
Onkologie|February 1, 1988
Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trialD W Beelen, U Graeven, G Schulz, et al.
Bone Marrow Transplantation|June 29, 2010
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndromeI Hilgendorf, D Wolff, T Gromke, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology studyD W Beelen, R B Schilcher, R Ehrlich, et al.
European Journal of Haematology|August 1, 1988
Bone marrow transplantation for myeloblastomaK Quabeck, D W Beelen, H K Mahmoud, et al.
Blood|January 7, 1998
Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerismD W Beelen, H D Ottinger, A Elmaagacli, et al.
Antimicrobial Resistance and Infection Control|October 1, 2016
Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantationM Krull, I Klare, B Ross, et al.
Pageof 10